证券代码：835670 证券简称：数字人 公告编号：2022-091 山东数字人科技股份有限公司 关于接待机构投资者调研情况的公告 | --- | |--------------------------------------------------------------------| | | | 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假 | | 记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 | | 担个别及连带法律责任。 | 山东数字人科技股份有限公司（以下简称"公司"）于 2022 年 11 月 9 日 接待了 5 家机构的调研，现将主要情况公告如下： 一、 调研情况 调研时间：2022 年 11 月 9 日 调研地点：山东数字人科技股份有限公司会议室 调研形式：现场调研 调研机构：山东弘阳信基金管理有限公司、上海临彤资产管理有限公司、青 岛稳泰私募基金管理有限公司、安信证券股份有限公司、银河证券股份有限公司 上市公司接待人员：董事长徐以发先生 董事、副总经理、董事会秘书李相 东先生 二、 调研的主要问题及公司回复概要 问题 1、请问近期疫情对公司业务开展的影 ...

Financial Performance - The company's operating revenue for the current period is 7,145,928.19, a decrease of 68.10% compared to the same period last year, which was 22,398,249.14 [30]. - The net profit attributable to shareholders of the listed company is -14,147,839.48, representing a decline of 1,418.07% from -931,963.54 in the previous year [30]. - The total assets at the end of the current period amount to 239,733,083.38, down 9.58% from 265,127,970.96 at the end of the previous year [31]. - The net cash flow from operating activities is -15,037,521.56, a significant decline of 2,580.07% compared to -561,087.22 in the same period last year [32]. - The company's gross profit margin increased to 66.90% from 57.70% year-on-year [30]. - The company reported a significant increase in credit impairment losses, with a loss of -99,200.39 in the first half of 2022 compared to a gain of 1,282,363.48 in the same period of 2021 [158]. - The company reported a total comprehensive loss of CNY 14,441,748.73, compared to -931,963.54 in the first half of 2021 [159]. Research and Development - The company's R&D expenses for the first half of 2022 amounted to 11.92 million CNY, representing 166.82% of its operating revenue [14]. - The company has established two parallel R&D departments: the R&D Center and the Digital Human Research Institute, focusing on core technologies such as image acquisition and data processing [47]. - The company is focused on continuous technological innovation and product upgrades to meet evolving customer demands [14]. - The company has developed a 3D printed embryo model, which can be used in conjunction with its "Digital Embryo" system for teaching and demonstration [39]. - The company is committed to enhancing product quality and increasing R&D investment to maintain competitive advantages in technology and customer satisfaction [95]. Market and Competition - The company faces risks related to changes in industry policies that could adversely affect its operations if supportive measures are withdrawn [13]. - The company is exposed to market competition risks as the medical informationization industry accelerates, potentially impacting revenue growth [13]. - The demand for medical education products is expected to grow due to the aging population and increased government investment in medical education [46]. - The company is focusing on expanding its sales channels and enhancing its sales team to mitigate the impact of seasonal revenue fluctuations [88]. - The company is actively monitoring industry policy changes to adapt its strategies accordingly [87]. Corporate Governance - The company has established a complete corporate governance structure since its transformation into a joint-stock company in August 2015 [15]. - The actual controller, Xu Yifa, directly and indirectly controls 41.71% of the company's shares [15]. - The governance structure is being further standardized to ensure compliance with legal regulations and protect minority shareholders' interests [96]. - The company has committed to maintaining fair and equivalent compensation principles in related transactions [101]. - The company is focused on maintaining compliance with corporate governance standards to protect the interests of all shareholders [107]. Financial Management - The company distributed a cash dividend of 1.50 CNY per 10 shares and increased capital reserves by issuing 6 additional shares for every 10 shares held [8]. - The total amount of tax benefits and government subsidies received during the reporting period was 2.58 million yuan, which is a significant portion of the company's profits [15]. - The company has invested a total of RMB 85 million in various financial products, with no overdue amounts or expected impairments [74]. - The company approved the use of up to RMB 30 million of idle raised funds for purchasing low-risk financial products, with a decision valid for one year [75]. - The company has a commitment to ensure that any business dealings are conducted fairly and equitably [101]. Operational Challenges - The company acknowledges the potential adverse impact of the COVID-19 pandemic on its operations, particularly affecting client procurement plans [14]. - The company is committed to enhancing its internal control and risk prevention systems to ensure long-term stable development [50]. - The company has identified risks related to the loss of core technical personnel, which could adversely affect its R&D capabilities and operational performance [92]. - The company is actively enhancing its quality control systems to prevent product quality issues that could harm its market reputation [89]. - The company is at risk of adverse impacts on net profit if there are unfavorable changes to tax incentive policies related to the software industry [94]. Shareholder Information - The company has a total share capital of 106,182,400 shares [23]. - The largest shareholder, Xu Yifa, holds 40.85% of the shares, with a total of 43,378,037 shares after an increase of 16,266,764 shares during the reporting period [117]. - The total number of shareholders holding more than 5% of shares or among the top ten shareholders is 64,619,407, accounting for 60.86% of total shares [117]. - The company has not reported any breaches of commitments by its major shareholders or executives during the reporting period [106]. - The company has ongoing commitments to compensate investors for any losses incurred due to misleading information in securities transactions [102].

Financial Performance - The company's operating revenue for the current period is ¥7,145,928.19, a decrease of 68.10% compared to the same period last year, which was ¥22,398,249.14[30]. - The net profit attributable to shareholders of the listed company is -¥14,147,839.48, representing a decline of 1418.07% from -¥931,963.54 in the previous year[30]. - The total assets at the end of the current period amount to ¥239,733,083.38, down 9.58% from ¥265,127,970.96 at the end of the previous year[31]. - The company reported a net cash flow from operating activities of -¥15,037,521.56, a significant decline of 2580.07% compared to -¥561,087.22 in the previous year[32]. - The company's total comprehensive income for the first half of 2022 was -13,414,181.01, compared to -404,604.67 in the same period of 2021[163]. - The company incurred a comprehensive loss of -14,147,839.48 during the first half of 2022, contributing to the decline in total equity[171]. Research and Development - R&D expenses for the first half of 2022 amounted to 11.92 million CNY, representing 166.82% of the operating revenue[14]. - The company has developed over 100 digital medical education products, indicating a strong focus on research and development in the digital medicine sector[38]. - The company has established two parallel R&D departments: the R&D Center and the Digital Human Research Institute, focusing on core technologies such as image acquisition and data processing[47]. - The company emphasizes talent development and aims to establish a competitive compensation structure to attract and retain skilled personnel[49]. - The company has recognized the risk of technology innovation and is committed to timely updates and product upgrades to maintain its competitive edge[91]. Market and Competition - The company is exposed to market competition risks as the medical informationization industry accelerates, potentially impacting revenue growth[13]. - The company is positioned to benefit from the growing demand for medical education products due to ongoing reforms and increased government investment in medical education[46]. - The company plans to expand its overseas medical education market in alignment with the "Belt and Road" initiative, seizing historical development opportunities[49]. - The company is actively monitoring industry policy changes that could impact its operations, with a focus on adapting to new regulations[88]. Corporate Governance and Structure - The company has established a sound corporate governance structure since its transformation into a joint-stock company in August 2015[15]. - The actual controller of the company, Xu Yifa, directly and indirectly controls 41.71% of the shares[15]. - The company has committed to avoiding related party transactions and has adhered to this commitment without any violations during the reporting period[107]. - The board of directors and management team consists of 9 members, with a mix of experienced professionals in key positions[132]. Financial Management - The company received a total of 2.58 million yuan in government subsidies and tax benefits, which is a significant portion of its profit[15]. - The company has invested a total of RMB 85 million in various financial products, with no overdue amounts or expected impairments[75]. - The company reported a total investment income of RMB 140,506.85 from low-risk financial products during the first half of 2022[127]. - The company has not experienced any significant changes in the feasibility of its fundraising projects[127]. Risks and Challenges - The company faces risks related to changes in industry policies that could adversely affect operations if supportive measures are withdrawn[13]. - The company acknowledges the potential adverse impact of the COVID-19 pandemic on its operations, particularly affecting client procurement plans[13]. - There is a risk that changes in tax policies could adversely affect the company's future net profits[15]. - The company has faced substantial impacts on business expansion and implementation due to repeated COVID-19 outbreaks, affecting overall performance[61]. Shareholder Information - The total share capital of the company is 106,182,400 shares, with no preferred shares issued[23]. - The total number of unrestricted shares increased from 32,485,227 (48.95%) to 53,528,363 (50.41%) during the reporting period[114]. - The total number of restricted shares decreased from 33,878,773 (51.05%) to 52,654,037 (49.59%) during the reporting period[114]. - The company has maintained a performance guarantee deposit of 340,780.00 yuan, representing 0.14% of total assets, with no adverse impact on operations[111]. Product Development and Innovation - The "Digital Human Anatomy System" and "Medical Morphology Digital Teaching Platform" are key products aimed at improving teaching quality and efficiency in medical education[38]. - The company is developing personalized clinical data analysis systems and virtual surgical training systems to meet clinical needs[55]. - The company has formed partnerships with numerous medical universities since 2014, enhancing its R&D capabilities in high-precision digital human products[48]. - The company emphasizes brand building through technical and brand marketing, participating in exhibitions to increase product visibility[48].

Financial Performance - Operating revenue for Q1 2022 was CNY 3,474,903.37, representing a significant decline of 65.75% year-over-year due to COVID-19 impacts[16] - The net profit attributable to shareholders for Q1 2022 was a loss of CNY 5,403,616.84, a decrease of 384.09% compared to the same period last year[14] - The basic earnings per share for Q1 2022 was -CNY 0.08, down 300.00% from -CNY 0.02 in Q1 2021[14] - The total comprehensive loss for Q1 2022 was CNY -5,536,327.48, compared to CNY -1,189,168.53 in Q1 2021[55] - Total operating costs for Q1 2022 were CNY 10,802,812.75, down from CNY 14,808,765.24 in Q1 2021[53] - Net loss for Q1 2022 was CNY -5,536,327.48, compared to a net loss of CNY -1,189,168.53 in Q1 2021[55] - Other income for Q1 2022 was CNY 2,123,770.49, down from CNY 3,006,062.66 in Q1 2021[54] Cash Flow - The net cash flow from operating activities for Q1 2022 improved by 23.58%, amounting to -CNY 11,192,319.89 compared to -CNY 14,644,951.67 in the previous year[14] - Operating cash flow for Q1 2022 was negative at -11,192,319.89 yuan, compared to -14,644,951.67 yuan in Q1 2021, indicating an improvement of approximately 23.5% year-over-year[59] - Total cash inflow from operating activities was 8,384,786.97 yuan in Q1 2022, down from 16,813,319.46 yuan in Q1 2021, representing a decline of about 50%[59] - Cash outflow from operating activities totaled 19,577,106.86 yuan in Q1 2022, compared to 31,458,271.13 yuan in Q1 2021, showing a reduction of approximately 37.9%[59] - The net cash flow from financing activities was -426,927.38 yuan in Q1 2022, compared to a positive inflow of 13,043,475.00 yuan in Q1 2021[60] - The company reported a cash and cash equivalents balance of 82,949,508.81 yuan at the end of Q1 2022, down from 124,980,991.13 yuan at the end of Q1 2021[60] Assets and Liabilities - The total assets as of March 31, 2022, were CNY 259,612,846.78, a decrease of 2.08% compared to the end of the previous year[14] - The company's total equity attributable to shareholders decreased by 2.12% to CNY 249,100,149.53 as of March 31, 2022[14] - Total liabilities decreased to CNY 7,941,559.90 in Q1 2022 from CNY 9,746,735.77 in the previous year[51] - The total equity decreased to CNY 251,745,220.68 in Q1 2022 from CNY 256,809,847.90 in Q1 2021[51] - The total assets with restricted rights amount to CNY 340,780, representing 0.13% of total assets, related to a performance guarantee for a project[41] Shareholder Information - The number of ordinary shareholders as of the report date was 6,779[21] - The largest shareholder, Xu Yifan, holds 27,111,273 shares, representing 40.85% of total shares[22] - The second largest shareholder, Dongyuan Qihua, holds 2,712,000 shares, accounting for 4.09%[22] - The total shares held by the top ten shareholders amount to 40,109,823, which is 60.44% of the total[24] Commitments and Compliance - The company has ongoing commitments to avoid competition with its actual controllers and shareholders, initiated in January 2016, and is currently fulfilling these commitments[28] - The company has made commitments to reduce related party transactions, also initiated in January 2016, and is actively fulfilling these commitments[29] - The company has a commitment not to occupy company funds or assets, which started in January 2016, and is currently being fulfilled[29] - The company has a commitment regarding tax payment issues, ensuring personal liability for any losses incurred by the company due to tax withholding problems, initiated in January 2016, and is currently fulfilling this commitment[29] - The company has a lock-up commitment for shares issued on December 8, 2020, which is currently being fulfilled[30] - The company has commitments regarding share reduction intentions, initiated on December 8, 2020, and is actively fulfilling these commitments[30] - The company has a commitment to maintain stock price stability for three years after listing on the selected layer, initiated on December 8, 2020, and is currently fulfilling this commitment[30] - The company is committed to ensuring that there are no false records or misleading statements in the public offering documents[32] - The company acknowledges its legal responsibility for the accuracy and completeness of the public offering documents[32] - The company is committed to maintaining transparency and accountability in its financial disclosures[32] Legal and Regulatory Matters - There were no significant legal disputes or external guarantees reported during the period[27] - The company has not engaged in any major asset acquisitions or disposals during the reporting period[27] - There were no penalties or investigations reported against the company[27] - There are no overdue commitments or violations of promises made by the company during the reporting period[39] - The company has not undergone any asset seizures, freezes, or pledges during the reporting period[40]

Product Development and Innovation - The "High-definition Digital Human Virtual Anatomy Platform System" and "Digital Human High-definition 3D Printing Model" were recognized as reaching international advanced and leading levels respectively by experts from the Chinese Anatomical Society[7]. - The "Intelligent Cardiopulmonary Resuscitation Training System" was evaluated as reaching domestic leading level, addressing existing product deficiencies in the market[7]. - The company emphasizes the importance of continuous technological innovation and product upgrades to maintain its competitive edge in the digital medical software market[15]. - The company continues to increase investment in technology research and development, focusing on key technologies such as digital human technology, image recognition, and data processing[57]. - The company has established a research center and a digital human research institute to enhance its R&D capabilities, focusing on high-precision digital human products for clinical diagnosis and sports anatomy[58]. - The company plans to enhance its product offerings in the digital human technology sector, leveraging its established database and research capabilities[66]. - The company aims to strengthen its market presence in the medical education sector by optimizing its technology structure and enhancing product quality to improve core competitiveness[59]. - The company has established partnerships with over 400 medical institutions and has developed 13 invention patents and 62 copyrights[50]. Financial Performance - The company's operating revenue for 2021 was ¥83,717,513.88, a decrease of 16.77% compared to ¥100,583,059.71 in 2020[33]. - The net profit attributable to shareholders for 2021 was ¥15,939,794.48, down 45.17% from ¥29,070,135.08 in 2020[33]. - The gross profit margin for 2021 was 60.82%, a decline from 64.90% in 2020[33]. - The company's cash flow from operating activities for 2021 was ¥28,193,946.82, representing a significant increase of 1,008.92% compared to ¥2,542,478.16 in 2020[37]. - The company's total revenue for digital medical products reached ¥28,977,173.52, with a gross margin of 77.06%, reflecting a decrease of 24.53% compared to the same period last year[75]. - The revenue from clinical digital anatomy system solutions was ¥19,886,024.80, showing a significant increase of 66.70% year-on-year, although the gross margin decreased by 15.11% due to rising costs[79]. - The company reported a net loss of RMB 909,684.83 from its subsidiary, Shenzhen Yichuang Hongtu Technology Co., Ltd.[96]. - The company reported a total revenue of RMB 83,717,513.88 in 2021, with digital medical products contributing RMB 81,881,660.64, accounting for 97.81% of total revenue[107]. Market and Competition - Increased market competition is anticipated as the medical informationization industry accelerates, posing a risk to revenue growth if the company fails to meet evolving customer needs[14]. - The company faces risks from potential changes in national policies that could adversely affect the medical informationization industry[14]. - The company recognizes the urgent demand for medical education due to the talent gap exacerbated by the COVID-19 pandemic, providing a substantial growth opportunity in the medical education market[64]. - The digital medical education market is projected to have substantial growth potential, with over 700 medical colleges in China undergoing digital transformation[51]. - The company is focused on addressing the challenges in medical education, including resource shortages and imbalances in training across regions[123]. Governance and Risk Management - The company has established a sound corporate governance structure since its transformation into a joint-stock company in 2015[16]. - The actual controller, Xu Yifa, directly and indirectly controls 41.71% of the shares, which poses a risk of potential conflicts of interest[17]. - The company has established key internal controls related to revenue recognition to mitigate risks associated with inappropriate revenue reporting[108]. - The company emphasizes the importance of internal control and risk prevention to ensure long-term sustainable development[61]. - The company has made commitments regarding stock repurchase plans and maintaining stock price stability following its public offering[154]. Research and Development - The company invested CNY 20.82 million in R&D in 2021, accounting for 24.87% of its operating revenue[15]. - The company’s R&D team consists of over 100 members, ensuring technological leadership in the industry[51]. - The total number of R&D personnel decreased from 142 to 140, while the proportion of R&D personnel to total employees increased from 61.14% to 62.56%[103]. - The company has committed to enhancing medical education and providing high-quality products and services to improve healthcare standards[117]. Regulatory Environment - The company operates in a supportive regulatory environment for the healthcare information technology sector, which may change and impact future operations[18]. - The national policy encourages the development of educational information technology, aiming for comprehensive coverage of digital applications in education by 2022[121]. - The company is committed to timely tracking policy changes and adapting its strategies to maintain a competitive edge in the market[133]. Employee Management - The company adheres to the principle of "people-oriented," ensuring good compensation, benefits, and a supportive work environment for employees[117]. - The total number of employees increased from 227 to 229, with a net addition of 5 employees during the period[199]. - The number of master's degree holders among employees increased from 11 to 12[200]. - The company’s management compensation is based on a structured salary system including various components such as position salary and year-end bonuses[197]. Financial Management - The company is committed to improving its financial management system to enhance the quality of accounting information and support decision-making processes[61]. - The company has a performance guarantee deposit of 340,780.00 yuan, accounting for 0.13% of total assets, with no adverse impact on the company[164]. - The company has confirmed that there were no violations of commitments regarding competition during the reporting period, maintaining compliance with regulations[158].

证券代码：835670 证券简称：数字人 公告编号：2021-072 山东数字人科技股份有限公司 关于接待机构投资者调研情况的公告 | --- | |------------------------------------------------------------------------| | | | 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 | | 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 | | 带法律责任。 | 山东数字人科技股份有限公司（以下简称"公司"）于 2021 年 12 月 23 日 接待了 41 家机构的调研，现将主要情况公告如下： 一、 调研情况 调研时间：2021 年 12 月 23 日 调研地点：山东数字人科技股份有限公司会议室 调研形式：网络调研 调研机构：南方基金、华夏基金、国寿安保、财通基金、毅达资本、北京洪 泰同创投资管理有限公司、东源华信（北京）资本管理有限公司、米琳资本、淄 博国基新材料产业创业投资有限公司、淄博齐鲁创业投资有限责任公司、中航产 业投资有限公司、青岛晨鸣资产管理有限公司、星辰民航基金、合利投资、 ...